Skip to content

Study · In vitro (cells) · 2022

2 results

Blocking exosomal secretion aggravates 1,4-benzoquinone-induced mitochondrial fission activated by the AMPK/MFF/Drp1 pathway in HL-60 cells.

Lu F, Zhang Q, Zhang M, Sun S, Yang X, Yan H

Journal of applied toxicology : JAT22 May 2022Cited by 3 (Europe PMC)

PMID35383983 (opens in a new tab)DOI10.1002/jat.4328 (opens in a new tab)PepBankPUB-35383983
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In HL-60 cells, pre-treatment with SS‑31 attenuated the mitochondrial damage induced by 1,4-benzoquinone.

    In plain wordsIn lab-grown leukemia cells, SS‑31 reduced mitochondrial damage caused by a benzene metabolite.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Decrease1,4-BQ-induced mitochondrial damage
    Study

    humann: not reported in source

    HL-60 human promyelocytic leukemia cells exposed to 1,4-benzoquinone
    Outcome group
    Mitochondrial function · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon pre-treatment with the mitochondria-targeted antioxidant SS-31, there was attenuation of the mitochondrial damage induced by 1,4-BQ
    1 context sentence
    Title · context
    Blocking exosomal secretion aggravates 1,4-benzoquinone-induced mitochondrial fission activated by the AMPK/MFF/Drp1 pathway in HL-60 cells.
  2. 02LabIn vitro (cells)Mechanism

    In HL-60 cells exposed to 1,4-benzoquinone, SS‑31 pre-treatment was accompanied by a change in exosome release characteristics.

    In plain wordsIn lab-grown leukemia cells, SS‑31 pre-treatment came with a change in how the cells released exosomes.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedExosome release characteristics
    Study

    humann: not reported in source

    HL-60 human promyelocytic leukemia cells exposed to 1,4-benzoquinone
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon pre-treatment with the mitochondria-targeted antioxidant SS-31, there was attenuation of the mitochondrial damage induced by 1,4-BQ, accompanied by a change in the exosome release characteristics
    1 context sentence
    Title · context
    Blocking exosomal secretion aggravates 1,4-benzoquinone-induced mitochondrial fission activated by the AMPK/MFF/Drp1 pathway in HL-60 cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.